| Authors: |
Gasser R; Univ Toulouse, INSERM, CNRS, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France., Colin P; Univ Toulouse, INSERM, CNRS, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France., Jacquemard C; Faculty of Pharmacy, UMR 7200, CNRS, University of Strasbourg, Illkirch-Graffenstaden, 67400, France., Montagné T; Univ Toulouse, INSERM, CNRS, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France., Zhou Z; Viral Pathogenesis Unit, Department of Virology, Institut Pasteur, Paris, France.; Present address: HIPI (Human Immunology, Pathophysiology and Immunotherapy), INSERM U976, Hôpital Saint-Louis, Paris, France., Pons V; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM, UMR 1297, Université de Toulouse, Toulouse, F-31432, France., Kostenis E; Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany., Galés C; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM, UMR 1297, Université de Toulouse, Toulouse, F-31432, France. celine.gales@inserm.fr., Kellenberger E; Faculty of Pharmacy, UMR 7200, CNRS, University of Strasbourg, Illkirch-Graffenstaden, 67400, France. ekellen@unistra.fr., Lagane B; Univ Toulouse, INSERM, CNRS, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France. bernard.lagane@inserm.fr.; Viral Pathogenesis Unit, Department of Virology, Institut Pasteur, Paris, France. bernard.lagane@inserm.fr. |
